Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer.
Heather A ParsonsJustin RhoadesSarah C ReedGregory GydushPriyanka RamPedro ExmanKan XiongChristopher C LoTianyu LiMark FlehartyGregory J KirknerDenisse RotemOfir CohenFangyan YuMariana Fitarelli-KiehlKa Wai LeongMelissa E HughesShoshana M RosenbergLaura C CollinsKathy D MillerBrendan BlumenstielLorenzo TrippaCarrie CibulskisDonna S NeubergMatthew DeFeliceSamuel S FreemanNiall J LennonNikhil WagleGavin HaDaniel G StoverAtish D ChoudhuryGad A GetzEric P WinerMatthew MeyersonNancy U LinIan KropJ Christopher LoveG Mike MakrigiorgosAnn H PartridgeErica L MayerTodd R GolubViktor A AdalsteinssonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Tracking large numbers of individualized tumor mutations in cfDNA can improve MRD detection, but its sensitivity is driven by the number of tumor mutations available to track.